ROYALTY PURCHASE AGREEMENT dated as of January 6, 2018 between ANTIGENICS LLC, as Seller and HEALTHCARE ROYALTY PARTNERS III, L.P., AND CERTAIN AFFILIATED FUNDS IDENTIFIED HEREIN, collectively as PurchaserRoyalty Purchase Agreement • July 29th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
ROYALTY PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of January 6, 2018, by and between ANTIGENICS LLC, a Delaware limited liability company (the “Seller”) and the entities set forth on Schedule 1 in the proportions set forth thereon (collectively, the “Purchaser”).
Healthcare Royalty, Inc. Class A Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • July 29th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
Healthcare Royalty, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [29,411,765] shares and, at the election of the Underwriters, up to [3,308,824] additional shares of Class A common stock, par value $0.01 per share (“Stock”) of the Company, and the holder of the Company named in Schedule II hereto (the “Selling Stockholder”) propose, subject to the terms and conditions stated in this Agreement, to sell to the Underwriters an aggregate of [14,705,882] shares and, at the election of the Underwriters, up to [3,308,824] additional shares of Stock. The aggregate of [44,117,647] shares to be sold by the Company and the Selling Stockholder is herein called the Firm Shares, and the aggregate of [6,617,648] additional shares to be sold by the Company and the Selling Stockholder is herein called th
